Does the media favor UTHR or ORKA?

In the previous week, United Therapeutics had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 19 mentions for United Therapeutics and 14 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.85 beat United Therapeutics' score of 0.73 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 4 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GMAB or ORKA?

In the previous week, Oruka Therapeutics had 10 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Oruka Therapeutics and 4 mentions for Genmab A/S. Oruka Therapeutics' average media sentiment score of 0.85 beat Genmab A/S's score of 0.65 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 4 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ORKA or ASND?

In the previous week, Oruka Therapeutics had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 14 mentions for Oruka Therapeutics and 7 mentions for Ascendis Pharma A/S. Oruka Therapeutics' average media sentiment score of 0.85 beat Ascendis Pharma A/S's score of 0.48 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ORKA or EXEL?

In the previous week, Oruka Therapeutics had 8 more articles in the media than Exelixis. MarketBeat recorded 14 mentions for Oruka Therapeutics and 6 mentions for Exelixis. Oruka Therapeutics' average media sentiment score of 0.85 beat Exelixis' score of 0.61 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ORKA or BBIO?

In the previous week, Oruka Therapeutics had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Oruka Therapeutics and 10 mentions for BridgeBio Pharma. Oruka Therapeutics' average media sentiment score of 0.85 beat BridgeBio Pharma's score of 0.53 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 4 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Oruka Therapeutics (ORKA) Competitors

$89.93 -4.62 (-4.89%)

Closing price 04:00 PM Eastern

Extended Trading

$89.62 -0.32 (-0.35%)

As of 06:28 PM Eastern

Compare

ORKA vs. UTHR, GMAB, ASND, EXEL, and BBIO

Should you buy Oruka Therapeutics stock or one of its competitors? Oruka Therapeutics's main competitors and comparable companies include United Therapeutics (UTHR), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Exelixis (EXEL), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oruka Therapeutics compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

United Therapeutics presently has a consensus price target of $646.00, suggesting a potential upside of 31.99%. Oruka Therapeutics has a consensus price target of $133.00, suggesting a potential upside of 47.89%. Given Oruka Therapeutics' higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 8.6% of United Therapeutics shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, United Therapeutics had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 19 mentions for United Therapeutics and 14 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 0.85 beat United Therapeutics' score of 0.73 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	12 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	4 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to Oruka Therapeutics' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Oruka Therapeutics	N/A	-21.65%	-20.88%

United Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, meaning that its share price is 134% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.15B	6.65	$1.33B	$27.95	17.51
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Summary

United Therapeutics beats Oruka Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Oruka Therapeutics had 10 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Oruka Therapeutics and 4 mentions for Genmab A/S. Oruka Therapeutics' average media sentiment score of 0.85 beat Genmab A/S's score of 0.65 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	4 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a net margin of 19.08% compared to Oruka Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Genmab A/S currently has a consensus target price of $39.50, indicating a potential upside of 13.67%. Oruka Therapeutics has a consensus target price of $133.00, indicating a potential upside of 47.89%. Given Oruka Therapeutics' higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.83	$963M	$1.27	27.36
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

Summary

Genmab A/S beats Oruka Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Oruka Therapeutics (NASDAQ:ORKA) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

In the previous week, Oruka Therapeutics had 7 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 14 mentions for Oruka Therapeutics and 7 mentions for Ascendis Pharma A/S. Oruka Therapeutics' average media sentiment score of 0.85 beat Ascendis Pharma A/S's score of 0.48 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics has a beta of -0.34, indicating that its stock price is 134% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Oruka Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Ascendis Pharma A/S	$1.05B	13.29	-$258M	$12.89	17.31

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 70.99% compared to Oruka Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Oruka Therapeutics presently has a consensus target price of $133.00, suggesting a potential upside of 47.89%. Ascendis Pharma A/S has a consensus target price of $310.75, suggesting a potential upside of 39.27%. Given Oruka Therapeutics' higher probable upside, equities analysts plainly believe Oruka Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Ascendis Pharma A/S beats Oruka Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Exelixis?

Oruka Therapeutics (NASDAQ:ORKA) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Exelixis has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Exelixis	$2.32B	6.06	$782.57M	$3.18	17.84

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Oruka Therapeutics had 8 more articles in the media than Exelixis. MarketBeat recorded 14 mentions for Oruka Therapeutics and 6 mentions for Exelixis. Oruka Therapeutics' average media sentiment score of 0.85 beat Exelixis' score of 0.61 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics presently has a consensus price target of $133.00, indicating a potential upside of 47.89%. Exelixis has a consensus price target of $50.29, indicating a potential downside of 11.36%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Oruka Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

Oruka Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Oruka Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Exelixis	35.33%	42.17%	31.76%

Summary

Exelixis beats Oruka Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to BridgeBio Pharma?

Oruka Therapeutics (NASDAQ:ORKA) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

In the previous week, Oruka Therapeutics had 4 more articles in the media than BridgeBio Pharma. MarketBeat recorded 14 mentions for Oruka Therapeutics and 10 mentions for BridgeBio Pharma. Oruka Therapeutics' average media sentiment score of 0.85 beat BridgeBio Pharma's score of 0.53 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Oruka Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
BridgeBio Pharma	$502.08M	25.58	-$724.93M	-$3.57	N/A

Oruka Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Oruka Therapeutics has a beta of -0.34, suggesting that its share price is 134% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Oruka Therapeutics presently has a consensus price target of $133.00, suggesting a potential upside of 47.89%. BridgeBio Pharma has a consensus price target of $102.61, suggesting a potential upside of 56.16%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

BridgeBio Pharma beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORKA vs. The Competition

Export

Metric	Oruka Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.95B	$3.90B	$7.20B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	12.99%
P/E Ratio	-44.30	13.95	274.58	25.69
Price / Sales	N/A	1,382.16	647.39	85.37
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	9.28	15.30	10.44	6.32
Net Income	-$105.43M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-3.87%	-0.22%	0.53%	1.35%
1 Month Performance	-16.70%	-6.06%	-3.36%	-3.68%
1 Year Performance	477.96%	34.37%	16.04%	5.56%

Oruka Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORKA Oruka Therapeutics	3.7422 of 5 stars	$89.93 -4.9%	$133.00 +47.9%	+452.4%	$5.95B	N/A	N/A	68	News Coverage
UTHR United Therapeutics	4.2829 of 5 stars	$497.11 -1.3%	$646.00 +30.0%	+20.0%	$21.61B	$3.18B	17.79	1,400	Insider Trade
GMAB Genmab A/S	4.2685 of 5 stars	$32.47 +0.7%	$39.50 +21.7%	+23.1%	$20.10B	$4.13B	25.57	3,029
ASND Ascendis Pharma A/S	4.636 of 5 stars	$263.52 +0.9%	$310.00 +17.6%	+21.0%	$16.29B	$814.57M	20.44	1,189
EXEL Exelixis	2.3428 of 5 stars	$56.12 -2.3%	$50.07 -10.8%	+46.9%	$14.23B	$2.44B	17.65	1,077

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORKA) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oruka Therapeutics (ORKA) Competitors

ORKA vs. UTHR, GMAB, ASND, EXEL, and BBIO

How does Oruka Therapeutics compare to United Therapeutics?

Summary

How does Oruka Therapeutics compare to Genmab A/S?

Summary

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Oruka Therapeutics compare to Exelixis?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oruka Therapeutics (ORKA) Competitors

ORKA vs. UTHR, GMAB, ASND, EXEL, and BBIO

How does Oruka Therapeutics compare to United Therapeutics?

Do analysts prefer UTHR or ORKA?

Do insiders & institutionals believe in UTHR or ORKA?

Does the media favor UTHR or ORKA?

Is UTHR or ORKA more profitable?

Which has more risk & volatility, UTHR or ORKA?

Which has preferable valuation and earnings, UTHR or ORKA?

Summary

How does Oruka Therapeutics compare to Genmab A/S?

Does the media prefer GMAB or ORKA?

Do insiders & institutionals believe in GMAB or ORKA?

Is GMAB or ORKA more profitable?

Do analysts recommend GMAB or ORKA?

Which has more risk and volatility, GMAB or ORKA?

Which has higher earnings and valuation, GMAB or ORKA?

Summary

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Does the media favor ORKA or ASND?

Which has more risk and volatility, ORKA or ASND?

Which has better earnings & valuation, ORKA or ASND?

Do insiders and institutionals hold more shares of ORKA or ASND?

Is ORKA or ASND more profitable?

Do analysts rate ORKA or ASND?

Summary

How does Oruka Therapeutics compare to Exelixis?

Which has stronger earnings & valuation, ORKA or EXEL?

Do insiders & institutionals believe in ORKA or EXEL?

Does the media favor ORKA or EXEL?

Do analysts prefer ORKA or EXEL?

Which has more volatility & risk, ORKA or EXEL?

Is ORKA or EXEL more profitable?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Does the media refer more to ORKA or BBIO?

Which has higher earnings and valuation, ORKA or BBIO?

Is ORKA or BBIO more profitable?

Which has more volatility & risk, ORKA or BBIO?

Do insiders and institutionals hold more shares of ORKA or BBIO?

Do analysts rate ORKA or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools